arrow
P

Pedro Rocha

Hospital del Mar
H指数:18
被引数:1,155

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer

MET过表达与晚期非小细胞肺癌中更优的免疫治疗效果相关联

2025-11-270
OAAI
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

肺大细胞神经内分泌癌的整合分子与临床特征分析

2025-08-190
OA
MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer

MET通路抑制可增强小细胞肺癌的化疗-免疫治疗疗效

2025-06-200
OAAI
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer

DNA损伤应答特征与广泛期小细胞肺癌的一线化疗反应及肿瘤进化途径相关。

2025-03-200
OA
Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockade

接受免疫检查点阻断的转移性NSCLC患者的分子和免疫学特征与长期获益相关

2025-02-240
OA
Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study

Lurbinectedin联合Pembrolizumab治疗复发性小细胞肺癌: I/II期LUPER研究

2025-02-100
PRE
A technical approach to global plant genome editing regulation

全球植物基因组编辑调控的技术途径

2024-12-110
PRE
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
2024-11-190
OAAI
Spatial proteomic profiling unveils pre-existing anti-tumor immunity as a hallmark of exceptional benefit from immunotherapy in NSCLC
2024-03-220
PRE
Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer
2023-10-202
OAAI
Identifying long-term responders to immune checkpoint blockade: Potential utility of serum proteomic profiling in metastatic non-small cell lung cancer
2023-10-010
OAAI